Health and Wellness CSR News

Healthy Birth Outcomes Through Cross-Sector Collaboration

Article

A black baby in the U.S. is more than twice as likely to die before its first birthday as a white baby. In addition to the medical care and access a woman and baby receive, these poor outcomes are also driven by social determinants of health—non-clinical factors such as social, educational, environmental, and economic opportunities that affect a woman’s overall health and wellbeing. This multi-faceted challenge requires a multi-faceted approach.

Expanding Safe Water Access – An Urgent Global Need

By Silvia Cruz-Vargas, Sr. Manager, Global Citizenship & Sustainability at PepsiCo
Blog

Perhaps it goes without saying: no resource is more vital to humanity than water. And yet, 844 million people—one in ten worldwide—do not have access to #cleanwater. And demand for water is on the rise. The facts speak for themselves:

Aflac Partners with National Dance Marathon Leadership Conference for Corporate Social Responsibility Education

By Brian Golden
Article

In 2018, Aflac joined the Miracle Network Dance Marathon movement as partners for the annual Dance Marathon Leadership Conference (DMLC). DMLC fosters collaboration by sharing resources, best practices, and trends in peer-to-peer fundraising for participants involved with Dance Marathon programs at over 300 colleges and universities throughout North America.

Children's Miracle Network Hospitals: Behind the Scenes of a Video Shoot with Chloe

Article

As a national ambassador for Children’s Miracle Network Hospitals, Chloe, age 11, is just one of 10 million children treated each year at Children’s Miracle Network Hospitals.  This past week, Chloe took to the sky to fly to Columbus, GA, home of Aflac, a Children’s Miracle Network Hospitals partner to participate in a video shoot to create her story on surviving cancer, thanks to donations which helped her treatment at Asante Rogue Regional Medical Center.

Novartis Renews Drug Donation of Egaten® (Triclabendazole) Until 2022, Reaffirming Its Commitment to the Fight Against Liver Fluke

Summary: 
  • Novartis extends agreement with the WHO for the donation of Egaten® for the treatment of liver fluke, a neglected tropical disease, also known as fascioliasis, that infects more than 2.4 million people globally1
  • Since the start of the donation program in 2005, Novartis has donated approximately 4 million tablets of Egaten, valued at USD 41 million, helping to treat around 2 million fascioliasis patients worldwide

  • Egaten is currently the only treatment for fascioliasis recommended by the WHO and is on the WHO Model List of Essential Medicines

Novartis extends agreement with the WHO for the donation of Egaten® for the treatment of liver fluke, a neglected tropical disease, also known as fascioliasis, that infects more than 2.4 million people globally
Article
  • Novartis extends agreement with the WHO for the donation of Egaten® for the treatment of liver fluke, a neglected tropical disease, also known as fascioliasis, that infects more than 2.4 million people globally1
  • Since the start of the donation program in 2005, Novartis has donated approximately 4 million tablets of Egaten, valued at USD 41 million, helping to treat around 2 million fascioliasis patients worldwide

  • Egaten is currently the only treatment for fascioliasis recommended by the WHO and is on the WHO Model List of Essential Medicines

Novartis Announces US Renewables Agreement to Reduce Greenhouse Gas Emissions

Summary: 
  • Virtual Power Purchase Agreement (VPPA) with renewable energy company, Invenergy, adds 100 megawatts of clean power to the electrical grid.

  • VPPA expected to be online in 2019 and to reduce Novartis greenhouse gas emissions by more than 220,000 metric tons per year, equivalent to removing more than 48,000 passenger vehicles from the road each year

  • Electricity will be generated from Invenergy’s Santa Rita East wind farm near San Angelo, Texas

  • Project in line with Novartis’ sustainability goals to substantially reduce carbon footprint and increase use of renewable energies

Agreement expected to reduce Novartis greenhouse gas emissions by more than 220,000 metric tons per year, equivalent to removing more than 48,000 passenger vehicles from the road each year
Press Release
  • Virtual Power Purchase Agreement (VPPA) with renewable energy company, Invenergy, adds 100 megawatts of clean power to the electrical grid.

  • VPPA expected to be online in 2019 and to reduce Novartis greenhouse gas emissions by more than 220,000 metric tons per year, equivalent to removing more than 48,000 passenger vehicles from the road each year

  • Electricity will be generated from Invenergy’s Santa Rita East wind farm near San Angelo, Texas

  • Project in line with Novartis’ sustainability goals to substantially reduce carbon footprint and increase use of renewable energies

Merck Reinforces Commitment to Responsible Pricing

Press Release

KENILWORTH, N.J., July 20, 2018 /3BL Media/ -- Merck (NYSE:MRK), known as MSD outside the United States and Canada, has a long history of responsible pricing. In 2017, Merck issued its second annual Pricing Action Transparency Report, which showed that net prices across Merck’s U.S. product portfolio declined by 1.9 percent. We believe that further changes are still necessary to help reduce patient out-of-pocket costs. To demonstrate our commitment to achieving this goal, we are making the following announcement:

Science for a Cleaner, Healthier World

Johnson Matthey launches next phase of sustainable business framework, including ambitious new target to double positive impact of its products by 2025
Article

Johnson Matthey launches next phase of sustainable business framework, including ambitious new target to double positive impact of its products by 2025

Johnson Matthey, the global leader in science that makes the world cleaner and healthier, has set out its ambitious new sustainable business framework to drive growth and value creation in its latest annual report: matthey.com/ar-18

Booz Allen Interns Develop Innovative Solutions to Help Combat the Nation’s Opioid Epidemic

Blog

The opioid epidemic is ravaging communities across the United States. The issues surrounding addiction, treatment, and prevention are complex, and require an enormous level of collaboration among public safety and public health agencies. While there’s no single path forward to prevent opioid overdose deaths and treat opioid use disorder, it’s clear that innovative solutions are needed.

Gilead Supports AIDS Walk San Francisco

Multimedia with summary

This year, Gilead sponsored @aidswalksf, the largest #AIDS fundraising event in Northern California. 10,000 people participated in the 10k walk, and raised more than $1.8 million to benefit HIV/AIDS support organizations in the Bay Area. 

Pages

Subscribe to Health and Wellness